Skip to main content

Advertisement

Table 1 Baseline characteristics of patients with unresectable hepatocellular carcinoma who underwent either HAIC or TACE

From: Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study

Variable HAIC [cases (%)] TACE [cases (%)] P
Total 38 41  
Age (years) 0.638
 ≤ 60 27 (71.1) 27 (65.9)  
 > 60 11 (28.9) 14 (34.1)  
Gender 0.215
 Male 30 (78.9) 37 (90.2)  
 Female 8 (21.1) 4 (9.8)  
Tumor size (cm) 1.000
 < 10 12 (31.6) 12 (29.3)  
 ≥ 10 26 (68.4) 29 (70.7)  
Tumor number 0.654
 ≤ 3 18 (47.4) 17 (41.5)  
 > 3 20 (52.6) 24 (58.5)  
BCLC stage 0.338
 A 15 (39.5) 11 (26.8)  
 B 23 (60.5) 30 (73.2)  
Liver cirrhosis 0.368
 No 20 (52.6) 26 (63.4)  
 Yes 18 (47.4) 15 (36.6)  
Neutrophil: lymphocyte ratio 0.361
 ≤ 3 22 (57.9) 28 (68.3)  
 > 3 16 (42.1) 13 (31.7)  
Hemoglobin (g/L) 1.000
 < 100 1 (2.6) 1 (2.4)  
 ≥ 100 37 (97.4) 40 (97.6)  
Platelet count 1.000
 < 100 × 109/L 1 (2.6) 2 (4.9)  
 ≥ 100 × 109/L 37 (97.4) 39 (95.1)  
Hepatitis B surface antigen 0.434
 Negative 2 (5.3) 5 (12.2)  
 Positive 36 (94.7) 36 (87.8)  
HBV DNA (IU/mL) 0.593
 ≤ 1000 10 (26.3) 8 (19.5)  
 > 1000 28 (73.7) 33 (80.5)  
PT (s) 0.003
 ≤ 13.5 28 (73.7) 40 (97.6)  
 > 13.5 10 (26.3) 1 (2.4)  
ALT (U/L) 1.000
 ≤ 40 17 (44.7) 18 (43.9)  
 > 40 21 (55.3) 23 (56.1)  
ALB (g/L) 0.655
 ≤ 40 20 (52.6) 19 (46.3)  
 > 40 18 (47.4) 22 (53.7)  
TBIL (μmol/L) 0.284
 ≤ 20.5 27 (71.1) 34 (82.9)  
 > 20.5 11 (28.9) 7 (17.1)  
AFP (ng/mL) 0.813
 ≤ 400 12 (31.6) 15 (36.6)  
 > 400 26 (68.4) 26 (63.4)  
  1. HAIC hepatic artery infusion chemotherapy; TACE transarterial chemoembolization; BCLC Barcelona Clinic Liver Cancer; HBV hepatitis B virus; PT prothrombin time; ALT alanine transaminase; ALB albumin; TBIL total bilirubin; AFP alpha-fetoprotein
  2. P values were calculated using a two-sided Chi square test